REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > Polysaccharide > Dextrin Or Derivative Dextrin Or DerivativeDextrin Or Derivative patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021380 - Novel drug delivery compositions The present invention provides for a novel molecules useful for delivery of compounds to a mammal, more particularly for the intracellular delivery of nucleotides, nucleotide analogues or compounds with a heterocyclic base. Also provided for are novel therapeutic complexes comprising novel molecules complexed with nucleotide analogues or heterogeneous or homogenous ... 01/25/07 - 20070021379 - Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin. ... 01/18/07 - 20070015729 - Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof A novel cyclodextrin conjugate having poly(oxyethylene) as a spacer is non-toxic and forms highly biocompatible supramolecular structures exhibiting significant inclusive property and structural diversity, and thus, can be beneficially employed in various fields such as drug delivery, food and flavors, cosmetics, packing, textiles, separation processes, environment protection, fermentation and catalysis. ... 01/11/07 - 20070010487 - Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination ... 01/11/07 - 20070010486 - Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination ... 01/11/07 - 20070010485 - Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination ... 11/02/06 - 20060247208 - B-cyclodextrin derivatives and their use against anthrax lethal toxin The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivates displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition ... 10/19/06 - 20060234979 - Aripiprazole complex formulation and method An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or ... 10/12/06 - 20060229279 - Artemisinins with improved stability and bioavailability for therapeutic drug development and application A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, β-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one ... 10/12/06 - 20060229278 - Mitoquinone derivatives used as mitochondrially targeted antioxidants This invention relates to pharmaceutically acceptable amphiphilic antioxidant compounds, compositions and dosage forms comprising said compounds, and methods and uses reliant on said compounds. The compounds, compositions, dosage forms, uses and methods are useful in, for example, the treatment of diseases or conditions associated with oxidative stress. ... 10/12/06 - 20060229277 - Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor The present invention relates to pharmaceutical compositions containing an HMG-CoA reductase inhibitor which are protected from destabilization in acidic environments by utilizing an inclusion complexing agent, and further relates to their preparation and to their use in the treatment of hypercholesterolemia and hyperlipidemia. ... 09/07/06 - 20060199785 - Beta-cyclodextrin derivatives as antibacterial agents The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units. ... 08/31/06 - 20060194762 - Composition comprising an epothilone and methods for producing a composition comprising an epothilone The present invention concerns methods for the production of pharmaceutical formulations of Epothilones suitable for being administered parenterally, such as intravenously. ... 08/31/06 - 20060194761 - Olivetol-cyclodextrin complexes and regio-selective process for preparing delta 9-tetrahydrocannabinol A cyclodextrin-olivetol derivative complex is provided. The complex effectively blocks reaction at specific carbons to prevent unwanted reactions. A process for preparing a cannabinoid compound is further provided. The process comprises reacting at least one terpenoid with cyclodextrin-olivetol derivative complex to produce the cannabinoid compound. ... 08/24/06 - 20060189574 - Method of treating high plasma cholesterol levels A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant. ... 08/03/06 - 20060172970 - Methods for treatment and management of lung cancer using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or ... 07/27/06 - 20060166932 - Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second ... 07/27/06 - 20060166931 - Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof The present invention relates to the inclusion complexes of butylphthalide, which is D,L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin, in order to increase the ... 07/20/06 - 20060160767 - Method of providing food product with prolonged energy release The subject of the present invention is a nutritive composition for prolonged release of energy, characterized in that it comprises between 50 and 99.9%, preferably 60 to 99.9% and still more preferably between 70 and 99.9% by weight of branched maltodextrins having between 15 and 35% of 1-6 glucoside linkages, ... 07/06/06 - 20060148756 - Amphiphilic macrocyclic derivatives and their analogues Soluble amphiphilic macrocycle analogues having lipophilic groups attached to one side of the units making up the macrocycle and hydrophilic groups attached to the other side. These amphiphilic macrocyclic derivatives have the ability to self-assemble in aqueous solvent forming micelles or vesicles and can be used as hosts for the ... 06/22/06 - 20060135475 - Process for preparing an alpha-lipoic acid/cyclodextrin complex and product prepared The invention relates to a process for the preparation of a cyclodextrin/alpha-lipoic acid complex, wherein in a first step, an alpha-lipoic acid and a cyclodextrin are dissolved in an aqueous alkaline solution having a pH above pH 7, and in a second step an acid is added to lower the ... 06/22/06 - 20060135474 - Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b The present invention relates to improved methods for the production, isolation and purification of epothilone B. These methods include, for example, a fermentation process for the production of epothilone B, isolation via adsorption onto a resin, and subsequent purification. ... 06/22/06 - 20060135473 - Process for the preparation of piroxicam: b-cyclodextrin inclusion compounds The present invention relates to a process for the preparation of inclusion compounds of piroxicam with β-cyclodextrin. More particularly, according to the process of the invention, the aqueous solution of two components is subjected, before drying, to a freezing process at very high rate. The resulting products have physico-chemical characteristics ... 06/15/06 - 20060128658 - Biocompatible dialysis fluids containing icodextrins Icodextrin-based solutions and methods of making same that can be used during medical therapy, such as dialysis therapy are provided. The icodextrin-based solution at least includes a first solution containing icodextrin at a pH ranging from about 1.5 to about 5.0 and a buffer solution at a pH ranging from ... 05/25/06 - 20060111318 - Agent for treating eye diseases An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a ... 05/18/06 - 20060105993 - Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or ... 05/18/06 - 20060105992 - Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds This invention relates to compositions that contain cyclodextrin derivatives and selective estrogen receptor modulators and methods for the production of the compositions of the invention. The invention further relates of methods of administering the compositions of the present invention to a human or animal. ... 05/04/06 - 20060094691 - Inclusion complexes of rosiglitazone A host-guest complex, wherein the host is a cyclodextrin or a mixture of cyclodextrins (the Cyclodextrin) and the guest is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, (Compound (I)) or a pharmaceutically acceptable derivative thereof or a mixture thereof; a process for the preparation of said complex, a pharmaceutical composition comprising such complex and the use ... 04/27/06 - 20060089331 - Methods and compositions for reducing toxicity of a pharmaceutical compound The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more toxic effects. In ... 03/30/06 - 20060069065 - Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or ... 03/23/06 - 20060063737 - Liquid paroxetine compositions A liquid paroxetine composition containing at least 5 mg/ml of paroxetine or a pharmaceutically acceptable salt thereof, a non-carbohydrate sweetener, and a solvent containing 60-100% of ethanol, polyol or mixtures and 0-40% of water, provides for good stability and taste. ... 03/16/06 - 20060058262 - New injectable formulations containing progesterone The present invention relates to injectable progesterone formulations and processes for their preparation. ... 03/09/06 - 20060052341 - Control of a biological function A biological function is controlled via the autonomous delivery of formulations administered at a single site, by determining each of the preferred formulations having efficacy in effecting control of at least one stage of a preferred biological function and includes features of improved permeation of formulations to effect desired bioavailability ... 02/16/06 - 20060035862 - Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration The invention relates to new formulations for improving the local tolerance of intravenously administered 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof. ... 02/02/06 - 20060025380 - Formulations for non-parenteral use including hydrophobic cyclodextrins A novel system for non-parenteral formulations comprising cyclodextrins is disclosed. The system includes hydrophobic cyclodextrins and amino acids and homo- or co-polymers thereof. The cyclodextrins and amino acids form a complex with pharmaceutical and other ingredients to achieve greatly improved solubility and/or enhance stability. The complexes can be used for ... 01/19/06 - 20060014722 - Per (3,6-anhydro) cyclodextrin derivatives, their preparation and use thereof for separating ions, in particular chromium and manganese anions The invention relates to per(3,6-anhydro)cyclodextrin derivatives containing in C2 at least one carbamate group, polymers thereof, their preparation and their use for separating contaminating anions such as the anions CrO42−, Cr2O72− or MnO42−. ... 01/12/06 - 20060009420 - Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate The invention relates to aqueous formulations containing (−)-(R)-3-(2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions. ... 12/22/05 - 20050282776 - Injectable pharmaceutical compositions comprising sodium diclofenac and beta-cyclodextrin Injectable pharmaceutical compositions are described comprising sodium diclofenac, a β-cyclodextrin and a polysorbate, suitable for subcutaneous and intramuscular administration. ... 12/08/05 - 20050272701 - Pharmaceutical composition The present invention relates to a pharmaceutical composition containing a cycloalkene compound a salt thereof or a prodrug thereof, and a nonionic surfactant and/or a cyclodextrin derivative readily soluble in water, and a method for improving solubility, stability or coloring property of the compound, a salt thereof or a prodrug ... 12/08/05 - 20050272700 - Topical treatment and prevention of human papilloma virus (hpv) infection The present invention contemplates a topical pharmaceutical composition that comprises a medium containing an anti-viral-effective amount of the dietary indole or derivative thereof admixed with a dietary indole compound-complexing amount of a hydroxypropyl-β-cyclodextrin dissolved or dispersed therein. Another embodiment utilizes sorbitol to stabilize the indole. The indole compound remains stable ... 12/08/05 - 20050272699 - Acrylonitrile derivatives for inflammation and immune-related uses or a pharmaceutically acceptable salt, solvate or clathrate thereof. The variables for Structural Formula (I) are as described herein. ... 12/08/05 - 20050272698 - Liquid stable composition of oxazaphosphorine with mesna A low toxicity, stable oxazaphosphorine containing compositions with mesna for parenteral administration has been described. The process essentially requires addition of an oxazaphosphorine antineoplastic to the aqueous solution of an etherified β-cyclodextrin followed by addition of mesna as such or as an aqueous solution containing optionally, an etherified β-cyclodextrin. Preferably, ... 11/17/05 - 20050256083 - Preserved pharmaceutical compositions comprising cyclodextrins A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein. ... 11/10/05 - 20050250738 - Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are pleasant tasting, convenient to use, and chemically and physically stable. The liquid formulations can be administered directly or diluted before administration. Unlike the commercially available ZOLOFT™ ... 11/10/05 - 20050250737 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in ... 10/27/05 - 20050239748 - Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid Salts of 3-O-(3′,3′-dimethylsuccinyl)Betulinic acid (DSB) are disclosed. Particularly, the preparation, pharmaceutical evaluation, and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkali metal salt forms of DSB are disclosed. Pharmaceutical compositions including these salt forms are used in methods of treating HIV and related diseases. Methods of making the salts of ... 10/27/05 - 20050239747 - Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods Enhanced transdermal composition comprising a niosome, which retains within its structure a cyclodextrin inclusion complex of a steroidal active agent and a vesicle of nonionic surfactant are provided herein, which increases the permeability of dermal tissue to transdermally administered steroidal active agents. Methods for producing the enhanced transdermal composition as ... 10/27/05 - 20050239746 - Pharmaceutical composition This invention relates to a pharmaceutical composition containing an inclusion complex of propofol and a water soluble cyclodextrin, in freeze dried form. The invention also relates to a process for producing the composition and the composition in unit dose form. ... 10/20/05 - 20050234018 - Drug delivery to the back of the eye Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein. ... 10/20/05 - 20050234017 - Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of ... 10/13/05 - 20050227944 - Method of treating leishmaniasis using methyl-beta-cyclodextrin The present invention relates to a composition useful for the treatment of leishmaniasis said composition comprising pharmaceutically effective amount of methyl-beta-cyclodextrin, optionally along with other anti-leishmanial agent(s) and/or pharmaceutically acceptable additives, and a method thereof, wherein the said method reduces the cholesterol levels of the plasma membrane of the infected ... 10/06/05 - 20050222086 - Alprazolam inclusion complexes and pharmaceutical composition thereof A pharmaceutical composition an inclusion complex and methods for treating patients and preparing said complex disclosed for transmucosal delivery comprising an inclusion complex of (a) alprazolam and (b) a water soluble 2-hydroxypropyl-beta-cyclodextrin, and a pharmaceutically acceptable carrier therefor, wherein all the alprazolam is present in ring-closed form. ... 10/06/05 - 20050222085 - Quaternised ammonium cyclodextrin compounds Use of a compound of formula (I), wherein the symbol (a) represents a n-valent residue derived from a cyclodextrin compound by removing n of its hydroxyl groups; n is a number greater than 0 and represents the average number of substituents of formula (II) per molecule of said compound; h ... 09/29/05 - 20050215523 - Methods of using gamma cyclodextrin to control blood glucose and insulin secretion Disclosed are methods of producing a blunted postprandial glycemic response in an individual, and/or reducing postprandial insulin secretion, said methods comprising administering to the individual a nutritional or other product comprising gamma-cyclodextrin. Also disclosed are similar other methods directed toward the use of such products to provide weight and appetite ... 09/29/05 - 20050215522 - Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases Methods of reducing the risk of transmission of a sexually transmitted pathogen by contacting the pathogen or cells susceptible to infection by the pathogen with a β-cyclodextrin are provided. Methods for reducing the risk of transmission of a sexually transmitted pathogen to or from a subject by contacting the pathogen ... 09/29/05 - 20050215521 - Modafinil combination therapy for improving sleep quality One aspect of the present invention relates to pharmaceutical compositions comprising a compound that modulates the orexin system and a sedative agent. In a preferred embodiment, the compound that modulates the orexin system is modafinil and the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in ... 09/29/05 - 20050215520 - Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process The present invention relates to a process of preparing a water-soluble complex of water-insoluble or sparingly-soluble organic medicines and beta-cyclodextrin derivatives: a. dissolving successively or simultaneously the organic medicines and the beta-cyclodextrin derivatives in organic solvent(s) at certain mole ratio or mass ratio in the presence of suitable amount of ... 09/22/05 - 20050209190 - Camptothecin complexes Disclosed are compositions that include a camptothecin and an amorphous cyclodextrin. The camptothecin may be substituted or unsubstituted. Also disclosed are methods of treating undesirable or uncontrolled cell proliferation by administering the inventive compositions. Finally, implants including an implant structure and the inventive composition are disclosed. ... 09/22/05 - 20050209189 - Antiviral composition Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration ... 09/15/05 - 20050203060 - Methods of using thalidomide in combination with irinotecan This invention relates to compositions comprising thalidomide and irinotecan, which can be used in the treatment or prevention of colorectal cancer. The invention also relates to methods of treating or preventing colorectal cancer which comprise the administration of thalidomide and irinotecan to a patient in need of such treatment or ... 08/25/05 - 20050187189 - Artemisinins with improved stability and bioavailability for therapeutic drug development and application A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, β-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one ... 08/25/05 - 20050187188 - Methods for the treatment of a traumatic central nervous system injury The present invention provides methods for conferring a neuroprotective effect on a population of cells in a subject following a traumatic injury to the central nervous system. Specifically, the methods of the invention provide for the administration of a progestin or progestin metabolite following a traumatic brain injury. The progestin ... 08/18/05 - 20050182024 - Compositions of estrogen-cyclodextrin complexes Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since ... 08/18/05 - 20050182023 - Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process The preparation of semicarbazone and/or thiosemicarbazone formulations with cyclodextrins and their derivatives and products obtained by this process. The invention is characterized by obtaining inclusion compounds of semicarbazone and/or thiosemicarbazones with cyclodextrins and their derivatives, which were tested in experimental epilepsy models and allowed the reduction of the anticonvulsant dose ... 08/11/05 - 20050176681 - Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or ... 08/11/05 - 20050176680 - Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is ... 08/04/05 - 20050171057 - Pantoprazole cyclodextrin inclusion complexes An inclusion complex formed from pantoprazole and cyclodextrin is described. ... 07/28/05 - 20050164987 - Melatonin combination therapy for improving sleep quality One aspect of the present invention relates to pharmaceutical compositions comprising a sedative agent; and melatonin or a melatonin analog, collectively referred to as “melatonin agents.” In a preferred embodiment, the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. ... 07/28/05 - 20050164986 - Use of sulfoalkyl ether cyclodextrin as a preservative A method of preserving formulations is provided. The method includes the step of including a derivatized cyclodextrin in a formulation capable of sustaining microbial growth. One embodiment of the formulation employs a sulfoalkyl ether cyclodextrin as a preservative and optionally as a solubilizing and complexing agent. A suitable cyclodextrin is ... 07/14/05 - 20050153932 - Controlled muscle relaxation In general, embodiments of the present invention provide a method of applying controlled neuromuscular block in a surgical patient until the end of the surgical procedure comprising the steps of (1) inducement of deep neuromuscular block by intravenous administration of an initial bolus dose of a neuromuscular blocking agent, (2) ... 07/14/05 - 20050153931 - Novel natural cyclodextrin complexes The present invention is directed to the novel use of complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of α-CD, β-CD and γ-CD and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrahydrocannabinol and cannabidiol. ... 07/07/05 - 20050148544 - Compositions comprising cyclodextrin A stable composition for removing unwanted molecules from a surface comprises functionally-available cyclodextrin, cyclodextrin-compatible surfactant, and cyclodextrin-incompatible surfactant. The compositions are suitable for capturing unwanted molecules from inanimate surfaces, including fabrics, including carpets, and hard surfaces including countertops, dishes, floors, garbage cans, ceilings, walls, carpet padding, air filters, and the ... 07/07/05 - 20050148543 - Therapeutic formulations Formulations comprising one or more epothilones together with a pharmaceutically acceptable carrier. ... 06/30/05 - 20050143344 - Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone ... 06/30/05 - 20050143343 - Nutritional supplement for enhancing the production and effect of natural human growth hormone A nutritional supplement for enhancing the production and effect of natural human growth hormone. The nutritional supplement includes: L-arginine-2-pyrrolidone-5-carboxylate in an amount of about 500 milligrams to about 10 grams; L-lysine hydrochloride in an amount of about 500 milligrams to about 10 grams; and a cortisol suppressant including at least ... 06/09/05 - 20050124578 - Aqueous compositions containing metronidazole An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is niacin or niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed. ... 06/09/05 - 20050124577 - 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal ... ### FreshPatents.com Support |